Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia

被引：14
|
作者：
Zhang, Keyuan [1 ]
Zhang, Xiang [1 ]
Xu, Yang [1 ,2 ,3 ]
Xue, Shengli [1 ,2 ]
Qiu, Huiying [1 ,2 ]
Tang, Xiaowen [1 ,2 ,3 ]
Han, Yue [1 ,2 ,3 ]
Chen, Suning [1 ,2 ,3 ]
Sun, Aining [1 ,2 ]
Zhang, Yanming [4 ,5 ]
Wu, Depei [1 ,2 ,3 ,6 ]
Wang, Ying [1 ,2 ,3 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China
[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
[3] Minist Hlth, Key Lab Thrombosis & Hemostasis, Suzhou, Peoples R China
[4] Xuzhou Med Univ, Affiliated Huaian Hosp, Dept Hematol, Dept Neurosurg, 62 Huaihai Rd S, Huaian, Peoples R China
[5] Second Peoples Hosp Huaian, 62 Huaihai Rd S, Huaian, Peoples R China
[6] Soochow Univ, State Key Lab Radiat Med & Protect, Suzhou, Peoples R China
来源：
BLOOD CANCER JOURNAL | 2023年 / 13卷 / 01期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1038/s41408-023-00928-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
    Lachowiez, Curtis A.
    Loghavi, Sanam
    Furudate, Ken
    Montalban-Bravo, Guillermo
    Maiti, Abhishek
    Kadia, Tapan
    Daver, Naval
    Borthakur, Gautam
    Pemmaraju, Naveen
    Sasaki, Koji
    Alvarado, Yesid
    Yilmaz, Musa
    Short, Nicholas J.
    Chien, Kelly
    Ohanian, Maro
    Pierce, Sherry
    Patel, Keyur P.
    Jabbour, Elias
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Takahashi, Koichi
    Konopleva, Marina Y.
    DiNardo, Courtney D.
    BLOOD ADVANCES, 2021, 5 (08) : 2173 - 2183
  • [22] Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
    Mustafa Ali, Moaath K.
    Corley, Elizabeth M.
    Alharthy, Hanan
    Kline, Kathryn A. F.
    Law, Jennie Y.
    Lee, Seung Tae
    Niyongere, Sandrine
    Duong, Vu H.
    Emadi, Ashkan
    Baer, Maria R.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [23] Sequential Venetoclax and FLT3 Inhibitors in Combination With Hypomethylating Agents or Low-Dose Chemotherapy in Newly Diagnosed, Unfit, FLT3-Mutant Acute Myeloid Leukemia Patients
    Al Mahmasani, Layal
    Moukalled, Nour
    El Cheikh, Jean
    Bazarbachi, Ali
    Abou Dalle, Iman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S228 - S228
  • [24] VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IMPROVE THE REMISSION RATE IN OLDER OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
    Han, Xiao
    Song, Qingxiao
    Wan, Kai
    Zhang, Mengyun
    Liu, Xue
    Yan, Hongju
    Zhang, Cheng
    Wen, Qin
    Zhang, Xi
    BONE MARROW TRANSPLANTATION, 2024, 59 : 176 - 177
  • [25] Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax plus hypomethylating agents
    Johnson, Isla M.
    Karrar, Omer
    Rana, Masooma
    Iftikhar, Moazah
    Chen, Sunny
    McCullough, Kristen
    Saliba, Antoine N.
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Litzow, Mark
    Hogan, William J.
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Hermann, Joerg
    Tefferi, Ayalew
    Gangat, Naseema
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1232 - 1237
  • [26] Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBF/::MYH11(+) Acute Myeloid Leukemia
    Feng, Ziyu
    Hu, Xiaohui
    Li, Weiyang
    Xu, Ting
    Xu, Yang
    Xue, Shengli
    Qiu, Huiying
    Tang, Xiaowen
    Han, Yue
    Chen, Suning
    Sun, Aining
    Wu, Depei
    Wang, Ying
    BLOOD, 2024, 144 : 4287 - 4288
  • [27] Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
    Xu, Xuezhu
    Liu, Rui
    He, Aili
    Wang, Fangxia
    HEMATOLOGY, 2023, 28 (01)
  • [28] Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents.
    Zainaldin, Carl
    Arora, Sankalp
    Bathini, Sri
    Pandya, Vishruti
    Bae, Sejong
    Gupta, Udita
    Worth, Sarah
    Bachiashvili, Kimo
    Bhatia, Ravi
    Godby, Kelly Nicole
    Jamy, Omer
    Rangaraju, Sravanti
    Diamond, Barry
    Oliver, Josh D.
    Salzman, Donna E.
    Di Stasi, Antonio
    Vachhani, Pankit
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18808 - E18808
  • [29] Evaluating Venetoclax Treatment Duration When Combined with Hypomethylating Agents in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
    Uchida, Emma
    Lei, Matthew M.
    Brunner, Andrew M.
    Fathi, Amir T.
    Signorelli, Jessie
    BLOOD, 2021, 138
  • [30] Venetoclax combined with hypomethylating agents for favorable risk acute myeloid leukemia: A single center experience
    Bajwa, Shammas
    Parkin, Brian
    Gayle, Arlene A.
    Patel, Rushang D.
    Mori, Shahram
    Pancari, Philip
    Socola, Francisco Andres
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345